Caredx Inc(CDNA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 33.31 | EPS (ttm) | 2.07 | Insider Own | 8.98% | Shs Outstand | 51.5M | Perf Week | 3.01% |
| Market Cap | 3.57B | Forward P/E | 53.54 | EPS next Y | 7.7% | Insider Trans | -6.82% | Shs Float | 47.1M | Perf Month | 8.51% |
| Enterprise Value | 3.22B | PEG | 1.14 | EPS next Q | 0.25 | Inst Own | 99.79% | Short Float | 13.99% | Perf Quarter | 93.29% |
| Income | 0.11B | P/S | 7.8 | EPS this Y | 106.62% | Inst Trans | 0.57% | Short Ratio | 5.16 | Perf Half Y | 216.25% |
| Sales | 0.46B | P/B | 8.36 | EPS next 5Y | 46.93% | ROA | 22.72% | Short Interest | 6.59M | Perf YTD | 266.77% |
| Book/sh | 8.27 | P/C | 9.57 | EPS past 3/5Y | 34.67% 0.09% | ROE | 29.49% | 52W High | -4.96% ($72.71) | Perf Year | 361.59% |
| Cash/sh | 7.22 | P/FCF | 42.2 | Sales past 3/5Y | 5.68% 14.59% | ROIC | 25.3% | 52W Low | 385.76% ($14.23) | Perf 3Y | 1271.03% |
| Dividend Est. | - | EV/EBITDA | 179.2 | EPS Y/Y TTM | 90.73% | Gross Margin | 70.11% | Volatility(W/M) | 5.67% 6.25% | Perf 5Y | -1.02% |
| Dividend TTM | - | EV/Sales | 7.03 | Sales Y/Y TTM | 34.41% | Oper. Margin | -0.4% | ATR (14) | 3.79 | Perf 10Y | 1742.67% |
| Dividend Ex-Date | - | Quick Ratio | 4.51 | EPS Q/Q | 1412.42% | Profit Margin | 24.23% | RSI (14) | 63.74 | Recom | 1.57 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.58 | Sales Q/Q | 52.23% | SMA20 | 4.43% ($66.17) | Beta | 2.56 | Target Price | $64.17 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/10/29 | SMA50 | 19.93% ($57.62) | Rel Volume | 0.47 | Prev Close | $69.21 |
| Employees | 765 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 59.41% 15.69% | SMA200 | 112.46% ($32.52) | Avg Volume(3M) | 1.28M | Price | $69.1 |
| IPO | 2014/7/17 | Option/Short | Yes/Yes | Trades | 10082 | Volume | 603,131 | Change | -0.16% |
🧬 This is a US diagnostics company that develops and supplies precision diagnostic solutions for long-term transplant patients. Built on technology that uses non-invasive blood tests to detect the risk of organ rejection early, the company has established a differentiated position in managing transplant patients, including kidney and heart recipients.
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded less than usual. That is 47% of its average volume.
Next earnings report: October 29
2 days to go.
CDNA has a sound balance sheet but weak earning power
Of every $100 in sales, $0.40 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +106.6% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $5,354. Peers typically go for $2,743. Compared with its own 1-year average, it is 95% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -1.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 99.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #24 of 44 in the industry
Based on market cap of $4B.
FAQ
What kind of company is CDNA?
CDNA belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of CDNA?
The market cap of CDNA is approximately $3.6B, ranking 1,607 within its sector.
What is the P/E ratio of CDNA?
CDNA has a P/E ratio of approximately 33.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for CDNA?
CDNA has recorded a 52-week high of $72.71 and a low of $14.23.
